Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5252W HIGH $12.10
Volume
11.16 K
Value Traded
133.06 K
Short % Float
0.39%
-1.54%Week
-1.13%1 Month
-13.36%3 Month
+35.02%6 Month
+2.38%5 Year
+7.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
87.19 M
EPS (TTM)
0.37
P/E Ratio
25.82
Ent. Value
88.14 M
Total Shares
9.08 M
Float Shares
5.67 M
Insiders
37.62%
Institutions
14.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ICCC Catalyst Timeline
Dated clinical, regulatory and corporate events for ImmuCell Corporation
Past FDA Catalysts and PDUFA Decisions
How ICCC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
ImmuCell Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ICCC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| First Defense | prevention of scours (diarrhea) in newborn calves caused by rotavirus | 2015-02-25 | statistically significant effectiveness versus a placebo controlRead More | ImmuCell Reports Results From Rotavirus Pivotal Effectiveness StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| te Boekhorst Paul Francis OlivierDirector, Officer (President and CEO) | Buy | 8,000 17,785 held | $9.50 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ICCC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ICCC for Q2 2026. | ||||
ICCC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ICCC ranks across every disease it competes in
Competitive Position is a premium feature
See how ICCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialICCC News
ICCC▲ +2.6%today
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
ImmuCell Corporation reported a 46% increase in product sales for Q3 2026, totaling $8.0 million. Domestic sales rose by 29.2%, reflecting growth across its product lines, particularly Tri-Shield and Dual-Force. The company attributes this success to an expanded sales team and improved manufacturing. Future sales reporting will align with SEC standards.
Read more →ICCC▼ -7.8%on this news
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell Corporation reported its unaudited financial results for Q2 2026, showing a net income of $1.8 million and an 11.5% revenue increase to $7.2 million. The company experienced a significant acceleration in distributor volume growth, reaching 28%. However, gross margins declined due to lower manufacturing volumes and quality issues. ImmuCell is investing in capacity expansion to enhance production capabilities.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, on August 13, 2026. A conference call is scheduled for August 14, 2026, to discuss these results. The company expects no changes to its previously disclosed preliminary sales figures, indicating consistent performance.
Read more →ICCCImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
ImmuCell Corporation reported a 12% increase in product sales for Q2 2026, totaling $7.2 million, driven by a significant rise in domestic sales. The company also noted a 21% increase in sales for the first half of 2026 compared to the same period in 2025. Despite a decline in international sales, management remains optimistic about strong demand, particularly in Canada. A conference call is scheduled for August 14, 2026, to discuss these results in detail.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
ImmuCell Corporation reported strong unaudited financial results for Q1 2026, with net income rising to $1.9 million, up from $1.4 million in Q1 2025. Product sales experienced a significant increase of 28.4%, driven by high demand in the cow-calf segment. The company also announced plans for capacity expansion and improved manufacturing efficiencies, despite potential revenue moderation in the upcoming quarters.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
ImmuCell Corporation plans to announce its unaudited financial results for the quarter ended March 31, 2026, on May 14, 2026. The announcement will be followed by a conference call on May 15 to review these results. There is no expected change to the preliminary sales results disclosed earlier. ImmuCell specializes in animal health biologics, particularly solutions for improving calf health.
Read more →ICCC▲ +8.7%on this news
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
ImmuCell Corporation has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, effective April 15, 2026. The company is transitioning to a smaller, 7-person Board with six independent members and the CEO. This move includes the establishment of a Strategy and Technology Committee aimed at enhancing innovation and growth in their product line, First Defense.
Read more →ICCCImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
ImmuCell Corporation reported a 28.4% increase in product sales for Q1 2026, totaling $10.4 million. Domestic sales surged by 35.7%, primarily driven by the Tri-Shield® product. However, international sales experienced a decline of 30.2%. The company is optimistic about future growth, supported by new hires in its commercial team.
Read more →ICCCImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
ImmuCell Corporation has appointed Kathy Turner to its Board of Directors, effective April 1, 2026. She replaces Steven Rosgen, who is retiring after eight years. Turner has extensive experience in global healthcare and animal health, previously serving on the Board of Elanco Animal Health. Her role includes chairing the Compensation and Stock Option Committee.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
ImmuCell Corporation reported its unaudited financial results for the year ended December 31, 2025, showing a net operating income of $1.6 million, an increase from the previous year. Despite a net loss of $1.0 million, the company noted significant improvements in gross margin and manufacturing output. The management expressed optimism about future growth driven by strategic investments and enhanced customer engagement.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
ImmuCell Corporation will announce its unaudited financial results for the quarter and year ended December 31, 2025, on March 4, 2026. A conference call is scheduled for March 5, 2026, to discuss these results. The company expects no changes to the preliminary sales results disclosed earlier in January 2026.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
ImmuCell Corporation reported preliminary, unaudited sales results for Q4 and full year 2025, highlighting a 1.6% decline in Q4 sales but a 4.3% increase for the full year. The company is focusing on expanding its First Defense® product line following an FDA Incomplete Letter for Re-Tain®. Manufacturing improvements and a sales force expansion are planned to support growth.
Read more →ICCCImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
ImmuCell Corporation is set to hold a conference call on January 9, 2026, to discuss its strategic shift towards the First Defense® product line and away from Re-Tain®. The call will also cover unaudited sales results for Q4 and the full year 2025. The company aims to improve cattle health and productivity with its products.
Read more →ICCCImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain
ImmuCell Corporation (Nasdaq: ICCC) has shifted focus from its Re-Tain product to its First Defense franchise after receiving an Incomplete Letter from the FDA regarding the New Animal Drug Application. The company plans to expand its First Defense sales force and manufacturing capabilities, citing significant growth potential and customer confidence. Ongoing studies for Re-Tain will continue, but further investment will be paused due to potential delays in FDA approval. A non-cash impairment write-down is also anticipated as part of this strategic change.
Read more →ICCCImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
ImmuCell Corporation reported its unaudited financial results for the quarter ending September 30, 2025. The company's product sales highlighted an 8% decrease in the third quarter, though there was a 7% increase over the nine-month period compared to 2024. Notably, net income shifted to $1.8 million from a loss of $2.7 million in the same period last year, while gross margins improved significantly. Management noted sufficient inventory levels, potentially enhancing product adoption and revenue growth moving forward.
Read more →ICCCImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
ImmuCell Corporation will announce its unaudited financial results for Q3 2025 on November 13, 2025. Following this, a conference call is scheduled for November 14, 2025, to discuss the results. The company expects no changes to previously disclosed preliminary sales results. Investors can access additional information through the company's website.
Read more →ICCC▲ +5%on this newsshared move
ImmuCell Announces Onboarding of New CEO and Related Management Changes
ImmuCell Corporation has appointed Olivier te Boekhorst as the new President and CEO, effective November 1, 2025. He succeeds Michael F. Brigham, who will remain on the Board and serve as a Special Advisor. The company is also enhancing its leadership team with Timothy C. Fiori as CFO. A conference call is scheduled for November 14, 2025, to discuss financial results.
Read more →ICCCImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
ImmuCell Corporation announced preliminary, unaudited sales results for Q3 2025, indicating a decline in sales compared to previous quarters. This drop aligns with prior warnings about potential softening due to inventory re-stocking. The company remains committed to rebuilding market share and is working on developing a new treatment for mastitis in dairy cows.
Read more →ICCCImmuCell Announces Selection of its Next President and CEO
ImmuCell Corporation has appointed Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, who has a strong background in animal health and leadership roles at IDEXX Laboratories, is expected to drive growth for the company's products, First Defense® and Re-Tain®. Current CEO Michael F. Brigham will assist in the transition.
Read more →About ImmuCell Corporation
Headquarters56 EVERGREEN DR, PORTLAND, ME, 04103
BIOPHARMAWATCH ELITE PLUS
Trade the next ICCC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime